Upon joining the study, the patient is diagnosed with ST-elevation myocardial infarction (STEMI) and is scheduled for a procedure called primary percutaneous coronary intervention (pPCI).

The patient must be 18 years or older and provide informed consent to participate in the study.

The patient receives an intravenous infusion of cangrelor tetrasodium using a product called Kengrexal 50 mg powder for concentrate for solution for injection/infusion.

During the cangrelor infusion, the patient is also administered an oral dose of ticagrelor using Brilique 90 mg film-coated tablets.

The study aims to determine the best timing for administering ticagrelor. The patient is either given ticagrelor at the start of the cangrelor infusion or 30 minutes before the end of the infusion.

This timing is crucial to assess its effect on reducing high platelet reactivity, which is a condition where blood platelets are more likely to form clots.

The primary goal is to measure the incidence of high platelet reactivity using a test called the platelet function analyzer (PFA)-200 P2Y test.

The test measures the closure time (CT) of blood flow, with a CT of 106 seconds or less indicating high platelet reactivity.

The study also monitors for secondary outcomes such as major adverse cardiovascular events, mortality, stent thrombosis, unplanned revascularization, peri-procedural infarction, and bleeding events within 30 days.

The study is expected to conclude by December 31, 2025, with recruitment starting on June 1, 2024.